A non-interventional prospective study of 1-st line treatment approaches in OVArian cancer patients with HRD+ status in Russian Federation - OVARD

Inclusion Criteria

• • Patients ≥18 years of age;
• • Willing and ability to provide written informed consent for participation in the study;
• • Known status HRD+ (positive BRCAm test and/or positive Genomic Instability test);
• • Patients with histologically confirmed diagnosis of high-grade IC-IV FIGO stages epithelial ovarian, primary peritoneal, and/or fallopian tube cancer;
• • Completed primary treatment (surgery and/or 1st line CT +/- bevacizumab) no more than 3 months after completion of primary treatment.